Inclusion Criteria:

          -  PRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 0)

          -  Patients must have paraffin tissue from the diagnostic or relapse biopsy available to
             be submitted for central pathology review; this review is mandatory prior to
             registration to confirm eligibility and should be initiated as soon as possible

          -  ELIGIBILITY CRITERIA (STEP 1)

          -  Diagnosis of World Health Organization (WHO) diffuse large B-cell lymphoma, non-GCB by
             central review confirmation

          -  Patient must be deemed eligible to proceed with high-dose chemotherapy and autologous
             stem cell transplantation by local transplant center

          -  New York Heart Association class I or less; ordinary physical activity does not cause
             undue fatigue, palpitations, dyspnea, or angina pain; patients 60 years or older must
             have a left ventricular ejection fraction (LVEF) at rest >= 40% measured by
             echocardiogram or multi-gated acquisition (MUGA)

          -  Diffusion capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted
             (corrected or uncorrected for hemoglobin per institutional standards)

          -  Forced expiratory volume in 1 second (FEV1) >= 40% of predicted (corrected or
             uncorrected for hemoglobin per institutional standards)

          -  Forced vital capacity (FVC) >= 40% of predicted (corrected or uncorrected for
             hemoglobin per institutional standards)

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) unless isolated
             hyperbilirubinemia attributed to Gilbert's syndrome

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit
             of normal (ULN)

          -  Creatinine =< 2.0 mg/dL OR creatinine clearance (calculated clearance permitted) >= 40
             mL/min by Cockcroft-Gault formula

          -  Prothrombin time (PT)/ international normalized ration (INR) < 1.5 x ULN and partial
             thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN

          -  Patient must have progressed or be refractory to prior anthracycline-containing
             chemotherapy (e.g. rituximab, cyclophosphamide, doxorubicin hydrochloride,
             vincristine, and prednisone [R-CHOP], dose adjusted etoposide, prednisone,
             vincristine, cyclophosphamide, doxorubicin, and rituximab [DA-EPOCH-R], etc)

          -  No more than 3 prior regimens for large cell component (e.g. one induction and two
             salvage therapies); monoclonal antibody alone or involved field/involved site
             radiotherapy do not count as lines of therapy

          -  Prior use of ibrutinib is allowed unless patient has had disease progression while
             receiving ibrutinib

          -  Patient must have chemosensitive disease as defined by at least a partial response to
             salvage therapy at their latest assessment

          -  No major surgery =< 7 days prior to registration and no minor surgery =< 3 days prior
             to registration (with the exception of intravenous access placement, e.g. Hickman or
             peripherally inserted central catheter [PICC])

          -  Not pregnant and not nursing, because this study involves an agent that has known
             genotoxic, mutagenic and teratogenic effects; therefore, for women of childbearing
             potential only, a negative serum pregnancy test must be obtained within 14 days prior
             to registration

               -  Women of childbearing potential must use adequate contraception from study start
                  to one month after the last dose of protocol therapy; adequate contraception is
                  defined as hormonal birth control, intrauterine device, double barrier method or
                  total abstinence; men must practice complete abstinence or agree to use an
                  adequate contraception method from study start to one month after the last dose
                  of protocol therapy

          -  Patients should not require chronic use of strong CYP3A inhibitors or strong CYP3A
             inducers

          -  Patients should not require concurrent therapeutic doses of steroids (> 20 mg of
             prednisone/day or equivalent) unless they need them for the indications; steroids
             should be discontinued for 14 days before starting protocol treatment

          -  Human immunodeficiency virus (HIV) infected patients are eligible provided they meet
             all other eligibility criteria, and:

               -  There is no prior history of acquired immunodeficiency syndrome (AIDS) defining
                  conditions other than historically low CD4+ T-cell count or B-cell lymphoma

               -  In the opinion of an expert in HIV disease, prospects for long-term survival are
                  excellent were it not for the diagnosis of lymphoma

               -  Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a
                  pharmacologic booster is not allowed

               -  Zidovudine is not allowed

               -  Once daily combination pills for HIV containing a pharmacologic booster such as
                  cobicistat are not allowed

               -  Patients with multi-drug resistant HIV are not eligible

          -  Patients cannot have:

               -  Active central nervous system or meningeal involvement by lymphoma; patients with
                  a history of central nervous system (CNS) or meningeal involvement must be in a
                  documented remission by cerebrospinal fluid (CSF) evaluation and
                  contrast-enhanced magnetic resonance imaging (MRI) imaging for at least 91 days
                  prior to registration

               -  Evidence of myelodysplasia or cytogenetic abnormality indicative of
                  myelodysplasia on any bone marrow biopsy prior to initiation of therapy

               -  A known bleeding diathesis

               -  Requirement for warfarin or similar vitamin K antagonists; these drugs are
                  prohibited 28 days prior to the first treatment and throughout the trial

               -  History of stroke or intracranial hemorrhage =< 6 months before treatment

               -  Currently active, clinically significant hepatic impairment (Child-Pugh class B
                  or C according to the Child Pugh classification

               -  History of allergic reactions attributed to compounds of similar chemical or
                  biologic composition to ibrutinib or other agents used in study

               -  Serologic status reflecting active hepatitis B or C infection; patients that are
                  positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or
                  hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior
                  to enrollment; (PCR positive patients will be excluded)

          -  Eastern Cooperative Oncology Group (ECOG) performance status must be =< 2